<DOC>
	<DOCNO>NCT00515593</DOCNO>
	<brief_summary>The objective study - describe quality life begin Preotact® treatment end observational period ( Qualeffo-41 questionnaire ) - pain assessment begin Preotact® treatment end observational period ( VAS score ) - describe bone mineral density begin Preotact® treatment end observational period ( T-Score ) - describe incidence bone fracture cause osteoporosis well pathological finding skeleton begin Preotact® treatment - describe serum level calcium bone resorption marker desoxypyridinoline ( DPD ) N- respectively C-terminal crosslink-telopeptide ( CTX NTX ) begin Preotact® treatment end observational period ( subgroup patient , physician see need measure parameter ) - document adverse drug reaction begin Preotact® treatment - analysis subgroup different risk bone fracture cause osteoporosis begin Preotact® treatment - ass manageability function Pen system injection Preotact® ( self administer questionnaire )</brief_summary>
	<brief_title>PROPOSE Quality - PReOtact Postmenopausal OStEoporosis - Quality Life Study ( FP-004-DE )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion require Preotact® prescribe accordance SPC state contraindication strictly consider . Caution take treat Physician concern precaution , warning potential drug interaction state SPC . No inclusion exclusion parameter define . The decision individual application Preotact® strictly make physician .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal woman</keyword>
	<keyword>Severe postmenopausal osteoporosis</keyword>
</DOC>